Vericel Corporation ( (VCEL) ) has released its Q3 earnings. Here is a breakdown of the information Vericel Corporation presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Vericel Corporation is a prominent player in the advanced therapies sector, focusing on sports medicine and severe burn care. The company offers a unique portfolio of cell therapies and specialty biologics designed to repair injuries and restore lives.
In its third-quarter 2025 financial report, Vericel Corporation announced a record total revenue of $67.5 million, marking a significant milestone for the company. The report highlights substantial growth in its MACI product line and a notable increase in net income, reflecting the company’s strong market position and strategic initiatives.
Key financial metrics from the report include a 25% growth in MACI revenue to $55.7 million and a net income of $5.1 million. The company also achieved a record operating cash flow of $22.1 million and maintained a robust gross margin of 73.5%. Additionally, Vericel reported a 69% increase in non-GAAP adjusted EBITDA to $17.0 million, underscoring its enhanced profitability.
Vericel’s business highlights include the expansion of its MACI sales force and the initiation of a clinical study for the MACI Ankle program. The company also reported record quarterly revenue for NexoBrid, with a 38% growth compared to the previous year.
Looking ahead, Vericel Corporation is optimistic about its future prospects, with management confident in achieving sustained high revenue and profit growth. The company is well-positioned to close the year strongly and continue its growth trajectory into 2026 and beyond, leveraging its core portfolio and ongoing strategic initiatives.